BridgeBio Pharma, Inc.: BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1

Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of encaleret across key clinical parameters in ADH1 - All pre-spec ...

BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1

Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of ...

Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update

Opus Genetics Virtual R&D Science Forum Scheduled for Tuesday, June 16, 2026, at 10:00 am ETUpcoming Data Readout for Cohort 1 of OPGx-BEST1 ...
Hosted on MSN

From Punnett Squares to Patient Care: How 2026 BSN Students Master Genetics for Real-World Nursing

As the 2025/2026 nursing curriculum evolves, BSN students are finding that genetics is no longer an abstract concept confined to Punnett squares. With new test banks and guides from SimpleNursing and ...

Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases

Detailed price information for Opus Genetics Inc (IRD-Q) from The Globe and Mail including charting and trades.
MoneyWeek

What is a trust – and should you use it to avoid inheritance tax?

Government plans to make inheritance tax due on pensions, plus other changes to IHT rules, have seen a leap in people enquiring about the use of trusts to protect their wealth. So what are trusts, and ...